1[1]Malbrain ML, Van den Bergh H, Zachee P,et al. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon alpha in a case with a unique chromosomal abnormality[J]. Br J Haematol, 1996,92 (1):176-183.
2[2]Fruebauf S, Fiehn C, Haas R, et al. Sustained remission of idiopathic hyereosinophilic syndrome following alphainterferon therapy[J]. Acta Haematol, 1993,89 (2):91-93.
8[10]Vardiman JW, Harris NL, Brunning RD. The World Health Organization(WHO) classification of myeloid neoplasms[J]. Blood, 2002,100(7):2292-2302.
9[11]Vandenberghe P, Wlodarska I, Michaux L,et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias[J]. Leukemia, 2004,18(4):734-742.
5PrinL. Heterogeneity of human eosinophil glucocorticoid receptor correlation with resistance to corticotherapy[J]. Clin EXP Immunol, 1989,78:383.
6Metzgeroth G. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-Ⅱ study [J]. Br J Haematol, 2008,143(5) :707-715.
7Quintds-Cardaraa A. Therapeutic options for patients with clonal and idiopathic hypereosinophia[J]. Expert Opin Investig Drugs, 2008,17(7) : 1039-1050.
